IMPORTANCE Early detection of choroidal melanoma at a small tumor size is emphasized in the literature. However, there is little published information on the specific risks of plaque-irradiated small choroidal melanoma on visual acuity and metastasis.
T here is considerable attention to the early identification and treatment of small choroidal melanoma, generally defined as a tumor 3 mm or less in thickness (<3.5 mm, rounded to the whole number). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Small choroidal melanoma can clinically simulate nevus, and there are clinical, cytologic, and cytogenetic features that can serve to differentiate these conditions. 5, 6, [8] [9] [10] [11] [12] Clinical risk factors, such as greater tumor thickness, presence of symptoms, subretinal fluid, orange pigment, ultrasonographic hollowness, and tumor location near the optic disc, among others, are routinely used to identify choroidal melanoma at its earliest point, a time when intervention could affect life prognosis. 5, 8 Cytogenetic abnormalities in chromosomes 3, 6, and 8 are likewise important in melanoma risk for metastasis. 11 Arecent analysis of 1059 patients with uveal melanoma revealed several clinical findings that were predictive of cytogenetic alterations associated with high-risk status for metastasis. 12 Regarding tumor size, chromosome 3 mutation was found in 35% of small melanomas (≤3 mm thickness), 52% of medium melanomas (>3 to 8 mm), and 65% of large melanomas (>8 mm), correlating with metastatic risk. 11 A recent publication 13 has demonstrated that choroidal nevi with slow growth to melanoma (>1 year) are cytogenetically less aggressive than nevi with fast growth (≤1 year). Kim et al 14 and Shields et al 15 have evaluated techniques and complications of genetic testing of small melanoma, and, despite thin tumors, a 91% yield for cytopathology was achieved.
Regardless of the effort in the early detection of uveal melanoma, there remains little information on the specific risks of plaque-irradiated small choroidal melanoma on visual acuity and metastasis. In this study, we focus on small choroidal melanoma managed conservatively with plaque radiotherapy to assess visual outcome and precise risk for metastasis for the entire patient group and by single-millimeter and partialmillimeter thickness increments.
Methods
A retrospective medical record review was performed for all patients diagnosed with small choroidal melanoma measuring 3.4 mm or less in thickness (or ≤3 mm by whole-number measurements) by ocular ultrasonography who were managed with plaque radiotherapy on the Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, from June 27, 1977 , to December 21, 2015 . This study was approved by the institutional review board of the study institution and adhered to the tenets of the Declaration of Helsinki. Informed consent was waived because of the use of deidentified patient data.
Some of the patients in this analysis may have been included in previous analyses on clinical features and risk factors for tumor growth, multi-imaging features, and outcomes analyses. However, this is to our knowledge the first study from our department specifically focused on plaque radiotherapy for small choroidal melanoma.
All patients underwent slitlamp biomicroscopy of the anterior segment of the eye and indirect ophthalmoscopy of the fundus by 1 of the 2 senior authors (C.L.S. and J.A.S.), as well as imaging with ocular ultrasonography, fundus photography, fluorescein angiography, and optical coherence tomography (when available). The clinical data were collected retrospectively and included patient demographics, tumor features, treatment parameters, and outcomes for visual acuity, metastasis, and death.
At initial examination, the collected data included age, race/ ethnicity, sex, and affected eye (eTable 1 in the Supplement). The clinical features included best-corrected visual acuity (by logMAR or Snellen examination), presence of ocular melanocytosis, and anterior segment abnormalities. The tumor data included tumor location by tissue (iris, ciliary body, or choroid), quadrant (macula, inferior, temporal, superior, or nasal) , anteroposterior site (macula, macula-equator, equator-ora serrata, ciliary body, or iris), and distance to optic disc and foveola (millimeters). Tumor features included largest basal diameter, thickness measured on ultrasonography, and presence of associated features, such as subretinal fluid, orange pigment, drusen, Bruch membrane rupture, retinal invasion, extraocular extension, and vitreous hemorrhage ( Table 1) . Treatment parameters were listed, including previous therapies before plaque radiotherapy, radioisotope used with dose (Gray) and dose rate (1 rad/h) to tumor apex, base, optic disc, foveola, and lens (eTable 2 in the Supplement).
Outcomes were recorded regarding visual acuity and visual acuity loss of 3 or more Snellen lines, radiation-associated complications, including maculopathy, papillopathy, neovascularization of the iris, disc, or retina, neovascular glaucoma, and vitreous hemorrhage, as documented in the medical record and judged from imaging. Time to systemic metastasis and melanoma-associated death were recorded ( Table 2) . Screening Table 2 ). Kaplan-Meier estimates were calculated for time to metastasis per 0.5-mm and 1.0-mm tumor thickness increments and compared across tumor thickness categories using the log-rank test ( Table 3) .
A series of univariable Cox regression analyses were performed to identify the factors associated with melanoma metastasis and death in the 1780 included patients, based on clinical features at presentation ( Table 4 and Table 5 ). All of the variables were analyzed as discrete variables except for patient age at presentation, tumor basal dimension, tumor thickness, and dis- tance of tumor to optic disc margin and foveola, which were evaluated as continuous variables. Subsequent multivariable analyses were performed using Cox proportional hazard model forward stepwise method for the factors identified as significant at the 5% level of significance. All significant analysis was performed using SAS version 13.2 (SAS Institute).
Results
In this analysis, there were 1780 consecutive patients with small choroidal melanoma treated with plaque radiotherapy. The results are tabulated in Tables 1 through 5 and eTables 1 through 5intheSupplement.
The patient demographic and visual acuity features are listed in eTable 1 in the Supplement. Briefly, visual acuity was 20/40 OU or better in 1276 of the patients (71.7%), and the mean (SD) visual acuity was 20/40 (20/50) OU (median, 20/30; range, 20/ 20 to counting fingers). The mean (SD) patient age at initial presentation was 58 (14) years (median, 59 years; range, 10-93 years). Most patients were white (n = 1752; 98.4%), and male and female participants were equally represented (n = 908 [51.0%] were female). Based on categorizations of patients by their ultimate development of melanoma-associated metastases, there were no significant differences in demographic features, presence of melanocytosis, and visual acuity at study entry.
The tumor features are listed in Table 1 The treatment parameters are listed in eTable 2 in the Supplement. Previous treatment was performed in 61 patients (3.4%), including transpupillary thermotherapy, plaque radiotherapy (at a center other than the one in which this study was conducted), photodynamic therapy, and laser photocoagulation. The median interval from first examination to plaque radiotherapy was less than 1 month (range, 0-1 month). The radioactive isotope used was generally iodine 125, and the calculated dose to the tumor apex was 84 Gy; to the base, 183 Gy; to the optic disc, 41 Gy; to the foveola, 67 Gy, and to the lens, 9Gy(eTable2intheSupplement). The mean (SD) follow-up time for this cohort was 74 (59) months (median, 55; range, 0-380 months). The number of patients followed up per length of time (in year increments) is listed in eTable 3 in the Supplement. Patient demographics and tumor features were evaluated based on follow-up of less than 5 years vs 5 years or more (eTables 4 and 5 in the Supplement).
Kaplan-Meier analyses of outcomes are listed in Table 2 and eFigures 3, 4, and 5 in the Supplement. The Kaplan-Meier rate of visual acuity loss (≥3 Snellen lines) was 9.5% (95% CI, 8.2%-11.0%) at 1 year, 39.2% (95% CI, 36.5%-42.0%) at 5 years, and 48.9% (95% CI, 45.6%-52.3%) at 10 years, whereas poor visual acuity (≤20/200) was 7.1% (95% CI, 5.9%-8.4%) at 1 year, 38.2% (95% CI, 35.5%-41.1%) at 5 years, and 53.5% (95% CI, 50.1%-57.1%) at 10 years. The rate of melanoma-associated metastases was 0.2% (95% CI, 0.09%-0.6%) at 1 year, 4.5% (95% CI, 3.4%-5.9%) at 5 years, and 8.8% (95% CI, 6.9%-11.1%) at 10 years. . Kaplan-Meier analysis at 5 and 10 years showed tumor recurrence at 6.5% (95% CI, 5.2%-8.0%) and 10.8% (95% CI, 8.7%-13.3%), and the need for enucleation (for any reason) at 4.0% (95% CI, 3.0%-5.3%) and 7.6% (95% CI, 5.8%-10.0%).
Metastatic rates per thickness increments are listed in Table 3 . Using the patients' tumor thicknesses at study entry in 0.5-mm increments, we found that the 10-year rate of metastasis were 25.0% (95% CI, 3.9%-87.2%) for those with 0.5-mm to 1.0-mm 
Discussion
The management of small choroidal melanoma continues to stimulate debate, and the controversy rests on the balance between tumor potential for metastasis and treatment effects on visual acuity. It is understood that increasing melanoma thickness is correlated with increasing risk for metastasis.
1 DienerWest et al 4 have provided a meta-analysis of 8 published studies on metastasis of uveal melanoma managed with enucleation and found the combined weighted estimate of 5-year mortality based on tumor size was 16% for cases of small melanoma (0-3 mm thickness), 32% for cases of medium-sized melanoma (3.1-8 mm thickness), and 53% for cases of large melanoma (>8 mm thickness). Later, results from the Collaborative Ocular Melanoma Study 16 (COMS) have revealed that 10-year melanoma-associated mortality for patients with large melanomas who had undergone enucleation was 40% vs 45% for those who had undergone enucleation combined with preenucleation radiotherapy. Additional data from COMS revealed that 12-year melanoma-associated mortality for patients who had had plaque radiotherapy for medium-sized melanoma was 21%, similar to that of patients who had undergone enucleation (17%).
17
There are to our knowledge relatively few data on outcomes after observation or treatment of small choroidal melanoma. In 1997, the COMS provided data on 204 patients with possible small choroidal melanoma (vs nevus) who were initially followed up because their tumors were not considered large enough to qualify for the clinical trial.
7 These tumors measured 5 mm or more in basal dimension and 1.0 to 3.0 mm in thickness, and 33% eventually required treatment because of growth within 5 years. The 8-year melanoma-specific mortality was 4%, but this figure included the 67% of tumors that did not qualify for treatment, so the true risk specific to the active, growing melanomas could be substantially greater. uveal melanoma, of which 1992 had active small choroidal melanoma managed with plaque radiotherapy, and the 10-year risk for melanoma-related metastasis was 12%.
In this analysis, we focused specifically on small choroidal melanoma outcomes following plaque radiotherapy. We found median tumor basal dimension at 8.0 mm and thickness at 2.7 mm, and multivariable risk factors for metastasis included older age, symptoms of photopsia, larger tumor base, greater tumor thickness, and evidence of previous treatment. After plaque radiotherapy, the 10-year rate of metastasis using 1.0-mm thickness increments was 25% for tumors 0 to 1.0 mm thick, with lower values for thicker tumors. The spike in metastasis in the thinnest tumors could be because of the exceptionally small cohort (n = 6, with only 1 event of metastasis), or this could represent the ominous diffuse choroidal melanoma, a subset of melanoma that demonstrates thin tumor with extensive basal dimension.
In fact, the mean basal dimension of these tumors was 7.8 mm (median, 7.8 mm, range, 2 mm-11.5 mm), while mean thickness/ base (percentage) ratio was 12%, supporting the clinical definition of diffuse uveal melanoma.
18 These patients often are followed up for a prolonged period under the diagnosis of choroidal nevus, and later, after documented growth, are referred for treatment. A previous study 18 comparing diffuse vs nondiffuse small choroidal melanoma revealed 15-year melanoma-associated death at 16% vs 6% (P < .001), and the disparity persisted even in the thinnest tumors (≤2 mm; 16% vs 4%; P = .01). Diffuse choroidal melanoma represents only 3% of all melanomas and is defined as tumor thickness of 20% or less relative to the tumor base (with a mean thickness of 2.0 mm), giving the tumor a flat or placoid appearance with a prominent basal diameter. visual acuity in 1106 eyes with uveal melanoma treated with plaque radiotherapy and found the 5-year rate of poor visual acuity (≤20/200 OU) was 24% for patients with small melanoma, 30% for patients with medium-sized melanoma, and 64% for patients with large melanoma. Based on multivariable analysis, 5 important clinical factors associated with poor visual acuity included older age, posterior location of tumor, proximity to the foveola, subretinal fluid, and increasing tumor thickness. These authors concluded that visual acuity was most effectively preserved in eyes with small melanoma outside a radius of 5 mm from the optic disc and foveola. 21 The COMS 22 subsequently provided 3-year visual outcomes for 623 patients randomized to plaque radiotherapy for medium-sized melanoma and found that visual acuity declined to less than or equal to 20/200 in 43% of those whose acuity had been better than 20/200 at initial presentation.
In this retrospective analysis, we found 5-year and 10-year rate of visual acuity loss equivalent to 3 or more Snellen lines at 39.2% and 48.9%, respectively. The 5-year and 10-year rates of poor visual acuity (≤20/200 OU) were 39.2% and 53.5%, respectively. Much of the vision loss was associated with radiation maculopathy (46.4% at 5 years and 59.0% at 10 years), radiation papillopathy (20.6% at 5 years and 30.1% at 10 years), and vitreous hemorrhage (11.7% at 5 years and 16.5% at 10 years), as well as features at initial presentation, including submacular tumor location and foveal serous retinal detachment. The median distance from the posterior tumor margin to the foveola was 2.0 mm and to the optic disc was 3.0 mm, which was typical for small choroidal melanoma because most are postequatorial in location. However, this location puts the eye at high risk for ultimate visual loss from radiationassociated ischemia and swelling.
Limitations
There are limitations in this retrospective analysis, including the unavailability of some data because of patient follow-up remote from our facility, a period of data collection that extended longer than 4 decades (during which time treatment philosophies and approaches have changed over this interval), and the possibility that patients might have intermittently received various treatments to improve visual acuity. In addition, even with the robust number of patients, the points of 15 and 20 years had relatively small numbers of patients, so these data should be interpreted with caution. Despite these drawbacks, this large cohort could prove useful for comparison to newer treatment regimens.
Conclusions
In summary, small choroidal melanoma can potentially be dangerous, with a 10-year risk for metastasis at 8.8%. This risk is highest in tumors with larger bases, greater thicknesses, increasing retinal detachment, and diffuse (flat) configurations. By comparison, this rate is far less than that of mediumsized or large melanomas, which had 10-year rates of metastasis at 25.4% and 48.7%, respectively. 1 We suggest that patients with potential small choroidal melanoma be evaluated by a qualified ophthalmologist or ocular oncologist for a timely diagnosis and prompt therapeutic intervention. Over the last several decades, ocular oncologists have set a goal to identify and treat smaller uveal melanomas. Another way to rephrase this goal would be to state that we want to identify melanocytic lesions that are likely to spread at some future time and ablate them before they do so. Ocular oncologists are very accurate in diagnosing medium and large uveal melanomas. Differentiation of small melanomas from high-risk choroidal nevi has been more challenging. Approximately 8% of people in the United States have a choroidal nevus. The malignant transformation rate is estimated at about 1 in 9000 per year. 1 This translates into about 2400 new cases of uveal melanoma each year in the United States, and the incidence seems to be increasing. Only about 30% of these lesions are diagnosed while they are small melanomas. So how does one differentiate the occasional small uveal melanoma from the thousands of benign choroidal nevi? In the past, significant documented growth of a small lesion often was used as a surrogate for malignant transformation. However, in a study of risk factors for metastasis, 2 growth of a lesion was associated with an 8-fold increase in metastasis. Identification of those lesions that will grow in the future is the goal. In addition, (10) 775 (44) 765 (45) 61 (62, 1 (1) 4 (4) 37 (41) 49 (54) 0.140 $ 0.233 58 (59, 20 (1) 171 (10) 775 (44) 814 (46) (99) 3 (<1) 17 (1) 5 (<1) 88 (97) 1 (1) 1 (1) (2) 10 (1) 54 ( (16) 177 (18) 229 (24) 114 (12) 16 (28) 14 (25) 7 (12) 14 (25) 6 (11) 0.4446 224 (31) 107 (15) 131 (18) 160 (22) 99 (14) 7 (21) (62) 215 (22) 27 (3) 11 (1) 3 (5) 37 (65) 16 (28) 1 (2) (1) 12 (1) 629 (65) 190 (20) 61 (6) 295 (30) 9 (16) 0 (0) 0 (0) 1 (2) 1 (2) 33 (58) 11 (19) 1 (2) 
